Andrew Olaye
University of Nottingham
7 Papers
Andrew Olaye is an academic researcher from University of Nottingham. The author has contributed to research in topics: Metachromatic leukodystrophy & Leukodystrophy. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Polymer carriers for drug delivery in tissue engineering
TL;DR: Synthetic polymers that have been used for tissue growth scaffold fabrication and their applications in both cell and extracellular matrix support and controlling the release of cell growth and differentiation supporting drugs are reviewed.
475
A systematic review of clinical effectiveness and safety for historical and current treatment options for metachromatic leukodystrophy in children, including atidarsagene autotemcel
TL;DR: Compared to NHx and HSCT, treatment with arsa-cel results in clinically relevant benefits in LI and EJ MLD patients by preserving cognitive function and motor development in most patients, and increased survival for LI patients.
7
EE45 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the Netherlands
Kelly Bean,Andrew Olaye,Rimma Velikanova,Beckley Miller,Karen Howle,Alexander Wilds,M Walz,Francis Pang +7 more
TL;DR: Arsa-cel as mentioned in this paper is a one-time ex-vivo gene therapy, potentially enabling affected children to retain their motor and cognitive function into adulthood and contribute to society.
1
EE408 Direct Cost Analysis Associated with the Management of Patients with Metachromatic Leukodystrophy (MLD) across Nine European Countries
TL;DR: The GMFC-MLD as discussed by the authors is a validated measure of motor dysfunction in MLD, which represents all clinically relevant stages from normal to loss of all gross motor function (generalized motor function) and each of the seven levels are associated with healthcare costs necessary to manage the condition.